The journal retracts the article " Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649723 | PMC |
| http://dx.doi.org/10.3390/molecules28217337 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Research progress on artemisinin and its derivatives in treatment of orthopedics-related diseases].
Zhongguo Zhong Yao Za Zhi
September 2024
Tianjin Hospital, Tianjin University (Tianjin Hospital) Tianjin 300211, China Tianjin Institute of Orthopedics Tianjin 300050, China Tianjin Key Laboratory of Orthopedic Biomechanics and Medical Engineering Tianjin 300050, China.
As research into the mechanisms of orthopedic diseases continues to deepen, the shortcomings of traditional single-target the-rapies are becoming increasingly apparent. Consequently, the search for multi-target drugs has become the mainstream research direction for orthopedics-related diseases. Artemisinin, a sesquiterpene lactone compound extracted from Artemisia annua, has led to the gradual synthesis of various derivatives such as dihydroartemisinin, artesunate, artemether, and arteether.
View Article and Find Full Text PDFThe Antiviral and Antimalarial Prodrug Artemisinin from the Species: A Review.
Curr Issues Mol Biol
October 2024
Research Institute of Integrative Life Sciences, Dongguk University-Seoul, Goyang-si 10326, Republic of Korea.
Artemisinin is a truly fascinating drug in many ways. Since the unrestrained procedure of its detection, as an antimalarial drug, artemisinin has received a great deal of consideration. Recently, application of artemisinin-based combination therapy has been broadly applied for treating numerous ailments.
View Article and Find Full Text PDFOptimization of in vivo antimalarial efficacy of combinations of aqueous leaf extracts of Artemisia annua L., Vernonia amygdalina Del, and Microglossa pyrifolia (Lam.) Kuntze using factorial design.
BMC Complement Med Ther
November 2024
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Jos, Jos, Nigeria.
Background: Malaria continues to be among the leading causes of mortality in Africa including Uganda, with the emergence of parasite resistance to the first-line therapeutics (Artemisinin- based Combination Therapy). To find new therapeutics, this study has reported an in vivo antimalarial efficacy of combinations of Artemisia annua (Aa), Vernonia amygdalina (Va), and Microglossa pyrifolia (Mp) in mice model using factorial design.
Methods: The Aa and Va were extracted by hot infusion, and Mp by cold maceration using distilled water.
Factors influencing health workers' adherence to malaria treatment guidelines in under-five children in Nigeria: A scoping review.
Malariaworld J
October 2024
Department of Pharmacology and Toxicology, National Institute for Pharmaceutical Research and Development, Federal Ministry of Health, Abuja, Nigeria.
Background: Malaria is a leading cause of mortality in children aged 5 years and below in Nigeria. Treatment guidelines stipulate among other recommendations, testing by microscopy or a rapid diagnostic test (RDT) before treatment. Non-adherence to these guidelines portends a challenge, especially among vulnerable under-five children.
View Article and Find Full Text PDFBackground: Malaria in pregnancy is a major public health issue, particularly among vulnerable populations in malaria-endemic sub-Saharan African countries. To mitigate its risks, WHO recommends sulphadoxine-pyrimethamine (SP) for chemoprevention and artemisinin-based combination therapy (ACT) to treat uncomplicated malaria. These interventions have helped to alleviate the risk associated with malaria in pregnancy; however, in the context of the emergence of SP- and ACT-resistant , maintained efficacy is under threat.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!